Study maps 30 rheumatoid arthritis biopsies, linking joint scarring to treatment resistance

Rheumatoid arthritis (RA) is a common autoimmune disease where the body’s immune system mistakenly attacks the lining of its own joints, causing chronic pain, swelling, and stiffness. While there have been remarkable advancements in the treatment of RA with an array of therapies that target inflammation, a large subset of patients (approximately 6–28%) continue to experience difficult-to-manage symptoms of disease even after receiving multiple lines of treatment.

There is a critical need to identify new therapeutic approaches for patients who are refractory to existing treatment options.

By looking closely at the biology of joint tissue, researchers at the Mass General Brigham Department of Medicine conducted a study, published in Nature Immunology, focusing on discovering why some people with rheumatoid arthritis don’t respond well to standard treatments. The paper is titled “Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis.”

Kevin Wei, MD, Ph.D., and Kartik Bhamidipati, Ph.D., of the Division of Rheumatology Inflammation and Immunity in, are the corresponding and lead authors.

The researchers leveraged cutting-edge spatial transcriptomics to profile over 30 joint biopsies from patients before and after they received treatment, providing them with a highly detailed “map” of joint tissues. They then asked which features within these joint tissue “maps” corresponded to a lack of adequate treatment response.

The team observed an exaggerated wound healing response (fibrogenesis) in the joints of patients who failed to achieve remission. Though the treatments were effective in depleting immune populations and reducing joint swelling, they were not adequately effective at alleviating joint pain in non-remitting patients, which was linked to increased tissue scarring.

The researchers also discovered that the buildup of scar tissue in joints happens because the normal communication between blood vessels and endothelial cells with nearby support cells, called fibroblasts, gets disrupted. The authors say that if they can find ways to help these cells talk to each other properly again, they may be able to stop or even reverse the harmful scarring that leads to ongoing joint problems.

Real-world implications

The study identifies this type of tissue scarring as a key driver of treatment-refractory RA. This mechanism remains unaddressed by the current therapeutic landscape and offers a novel, targetable pathway for patients resistant to existing treatments.

Advances in technology are speeding up the deep molecular profiling of patient samples, ushering in an exciting era of precision medicine for autoimmune diseases where treatment is tailored to a patient’s unique molecular characteristics (such as protein levels, enzyme activity, and more).

This targeted approach promises to replace the current trial-and-error treatment methods with more effective interventions, significantly improving patient outcomes and quality of life.